Retagliptin Phosphate

磷酸瑞格列汀

Report date: 2024/06/07 17:16:06
NME

Base Information

Drug NameRetagliptin Phosphate
Drug Alias NameRetagliptin phosphate tablets瑞泽唐SP-2086 PhosphateSP 2086
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes MellitusRenal Insufficiency
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2023/06/27
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesShandong Shengdi Pharmaceutical Co LtdShanghai Hengrui Pharmaceutical Co Ltd
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Inactive IndicationsRenal Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A